Noncontraceptive Benefits and Therapeutic Uses of the Oral Contraceptive Pill

The oral contraceptive pill is one of the most extensively studied medications ever prescribed. The health benefits are numerous and outweigh the risks of their use. Definitive evidence exists for protection against ovarian and endometrial cancers, benign breast disease, pelvic inflammatory disease requiring hospitalization, ectopic pregnancy, and iron-deficiency anemia. It has also been suggested that oral contraceptives may provide a benefit on bone mineral density, uterine fibroids, toxic shock syndrome, and colorectal cancer. Minimal supportive evidence exists for oral contraceptives protecting against the development of functional ovarian cysts and rheumatoid arthritis. Treatment of medical disorders with oral contraceptives is an ``off-label'' practice. Dysmenorrhea, irregular or excessive bleeding, acne, hirsuitism, and endometriosis-associated pain are common targets for oral contraceptive therapy. Most patients are unaware of these health benefits and therapeutic uses of oral contraceptives, and they tend to overestimate their risk. Counseling and education are necessary to help women make well-informed health-care decisions and improve compliance.

Noncontraceptive benefits - therapeutic uses - oral contraceptive pills - combination OCP

- 1 The Gallup Organization. Attitudes toward contraception: a poll conducted for the American College of Obstetricians and Gynecologists Princeton, NJ: March 1985 - 2 American College of Obstetricians and Gynecologists. Poll shows women still skeptical of contraceptive safety (press release) Washington, DC: ACOG; January 20 1994 - 3 Peipert J F, Gutmann J. Oral contraceptive risk assessment: a survey of 247 educated women. Obstet Gynecol . 1993; 82 112-117 - 4 Schlesselman J J. Cancer of the breast and reproductive tract in relation to use of oral contraceptives. Contraception . 1989; 40 1-38 - 5 The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med . 1987; 316 650-655 - 6 Schlesselman J J. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol . 1995; 85 793-801 - 7 Ness R B, Grisso J A, Cottreau C. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology . 2000; 11 111-117 - 8 Narod S A, Risch H, Moslehi R. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med . 1998; 339 424-428 - 9 Gross T P, Schlesselman J J. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol . 1994; 83 419-422 - 10 Prentice R L, Thomas D B. On the epidemiology of oral contraceptives and disease. Adv Cancer Res . 1987; 49 285-401 - 11 Schlesselman J J. Oral contraceptives and neoplasia of the uterine corpus. Contraception . 1991; 43 557-579 - 12 The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. JAMA . 1987; 257 796-800 - 13 Rosenblatt K A, Thomas D B, the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma. Int J Cancer . 1991; 49 870-874 - 14 Mishell Jr R D. Noncontraceptive benefits of oral contraceptives. J Reprod Med . 1993; 38 1021-1029 - 15 Peterson H B, Lee N C. The health effects of oral contraceptives: misperceptions, controversies, and continuing good news. Clin Obstet Gynecol . 1989; 32 339-355 - 16 Ory H W. The noncontraceptive health benefits from oral contraceptive use. Fam Plan Perspect . 1982; 14 182-184 - 17 Royal College of General Practitioners' Oral Contraception Study. Effect on hypertension and benign breast disease of progestagen component in combined oral contraceptives. Lancet . 1977; 1 624 - 18 Brinton L A, Vessey M P, Flavel R. Risk factors for benign breast disease. Am J Epidemiol . 1981; 113 203-214 - 19 Mishell Jr R D. Noncontraceptive health benefits of oral steroidal contraceptives. Am J Obstet Gynecol . 1982; 142 809-816 - 20 Rubin G L, Ory H W, Layde P M. Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol . 1982; 144 630-635 - 21 Wolner-Hanssen P, Svensson L, Mardh P. Laparoscopic findings and contraceptive use in women with signs and symptoms suggestive of acute salpingitis. Obstet Gynecol . 1985; 66 233-238 - 22 Wolner-Hanssen P, Eschenbach D A, Paavonen J. Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA . 1990; 263 54-59 - 23 Eschenbach D A, Harnisch J P, Holmes K K. Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors. Am J Obstet Gynecol . 1977; 128 838-850 - 24 Wolner-Hannsen P. Oral contraceptive use modifies the manifestations of pelvic inflammatory disease. Br J Obstet Gynaecol . 1986; 93 619-624 - 25 Panser L A, Phipps W R. Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease. Contraception . 1991; 43 91-99 - 26 Svensson L, Westrom L, Mardh P. Contraceptives and acute salpingitis. JAMA . 1984; 251 2553-2555 - 27 Franks A L, Beral V, Cates Jr W. Contraception and ectopic pregnancy risk. Am J Obstet Gynecol . 1990; 163 1120-1123 - 28 Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol . 1991; 78 291-298 - 29 Sivin I. International experience with NORPLANT and NORPLANT-2 contraceptives. Stud Fam Plann . 1988; 19 81-94 - 30 Vessey M, Metcalfe A, Wells C. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. BMJ . 1987; 294 1518-1520 - 31 Holt V L, Daling J R, McKnight B. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol . 1992; 79 529-533 - 32 Lanes S F, Birmann B, Walker A M, Singer S. Oral contraceptive type and functional ovarian cysts. Am J Obstet Gynecol . 1992; 166 956-961 - 33 Kleerekoper M, Brienza R S, Schultz L R. Oral contraceptive use may protect against low bone mass. Arch Intern Med . 1991; 151 1971-1976 - 34 Cooper C, Hannaford P, Croft P. Oral contraceptive pill use and fractures in women: a prospective study. Bone . 1993; 14 41-45 - 35 Vessey M, Mant J, Painter R. Oral contraception and other factors in relation to hospital referral for fracture: findings in a large cohort study. Contraception . 1998; 57 231-235 - 36 Michaëlsson K, Baron J A, Farahmand B Y. Oral contraceptive use and risk of hip fracture: a case-control study. Lancet . 1999; 353 1481-1484 - 37 Hall M L, Heavens J, Cullum I D, Ell P J. The range of bone density in normal British women. Br J Radiol . 1990; 63 266-269 - 38 Mazess R B, Barden H S. Bone density in premenopausal women: effects of age, dietary intake, physical activity, smoking and birth control pills. Am J Clin Nutr . 1991; 53 132-142 - 39 DeCherney A. Bone-sparing properties of oral contraceptives. Am J Obstet Gynecol . 1996; 174 15-20 - 40 Potter J D, McMichael A J. Large bowel cancer in women in relation to reproductive and hormonal factors: a case-control study. J Natl Cancer Inst . 1983; 71 703-709 - 41 Furner S E, Davis F G, Nelson R L. A case-control study of large bowel cancer and hormone exposure in women. Cancer Res . 1989; 49 4936-4940 - 42 Kune G A, Kune S, Watson L F. Oral contraceptive use does not protect against large bowel cancer. Contraception . 1990; 41 19-25 - 43 Weiss N S, Daling J R, Chow W H. Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. J Natl Cancer Inst . 1981; 67 57-60 - 44 Bostick R M, Potter J D, Kushi L H. Sugar, meat, fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States). Cancer Causes Control . 1994; 5 38-52 - 45 Fernandez E, La Vecchia C, Balducci A. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer . 2001; 84 722-727 - 46 Martinez M E, Grodstein F, Giovannucci E. A prospective study of reproductive factors, oral contraceptive use, and risk of colorectal cancer. Cancer Epidemiol Biomark Prev . 1997; 6 1-5 - 47 Wingrave S J. Reduction in the incidence of rheumatoid arthritis associated with oral contraceptives: Royal College of General Practitioners' Oral Contraception Study. Lancet . 1978; 1 569-571 - 48 Vandenbroucke J P, Boersma J W, Festen J JM. Oral contraceptives and rheumatoid arthritis: further evidence for a preventive effect. Lancet . 1982; 2 839-842 - 49 Pladevall-Vila M, Delclos G L, Varas C. Controversy of oral contraceptives and risk of rheumatoid arthritis: meta-analysis of conflicting studies and review of conflicting meta-analyses with special emphasis on analysis of heterogeneity. Am J Epidemiol . 1996; 144 1-14 - 50 Ross R K, Pike M C, Vessey M P. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ . 1986; 293 359-362 - 51 Chiaffarino F, Parazzini F, La Vecchia C. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynecol . 1999; 106 857-860 - 52 Parazzini F, Negri E, La Vecchia, Fedele L, Rabaiotti M, Luchini L. Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol . 1992; 79 430-433 - 53 ACOG Practice Bulletin Number 18. The Use of Hormonal Contraception in Women with Coexisting Medical Conditions. July 2000 - 54 Gray R H. Toxic shock syndrome and oral contraception [letter]. Am J Obstet Gynecol . 1987; 156 1038 - 55 Schwartz B, Gaventa S, Broome C V. Nonmenstrual toxic shock syndrome associated with barrier contraceptives: report of a case-control study. Rev Infect Dis . 1989; 11(suppl) S43-S48 - 56 Reingold A L, Broome C V, Gaventa S. Risk factors for menstrual toxic shock syndrome: results of a multi-state case-control study. Rev Infect Dis . 1989; 11(suppl) S35-S41 - 57 Privrel T, Daubenfeld O. Clinical experience in Switzerland with the new monophasic oral contraceptive Minulet (75 μg gestodene, 30 μg ethinyl estradiol). Br J Clin Pract . 1988; 42 292-298 - 58 Ulstien M, Svendsen E, Steier A. Clinical experience with a triphasic oral contraceptive. Acta Obstet Gynecol Scand . 1984; 63 233-236 - 59 Klein J R, Litt I F. Epidemiology of adolescent dysmenorrhea. Pediatrics . 1981; 68 661-664 - 60 Lavin C. Dysfunctional uterine bleeding in adolescents. Curr Opin Pediatr . 1996; 8 328-332 - 61 Davis A, Godwin A, Lippman J. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol . 2000; 96 913-920 - 62 Iyer V, Farquhar C, Jepson R. Oral contraceptive pills for heavy menstrual bleeding (Cochrane Review). In: The Cochrane Library Issue 2. Oxford: Update Software; 1999 - 63 Chuong C J, Brenner P F. Management of abnormal uterine bleeding. Am J Obstet Gynecol . 1996; 175 787-792 - 64 Arias R D. Therapeutic uses of oral contraceptives. In: Arias RD, ed. Benefits and Risks of Oral Contraceptives: A Current Perspective Little Falls, NJ: Health Learning System, Inc. 1997: 55-59 - 65 Raj S G, Raj N H, Talbert L M. Normalization of testosterone levels using a low estrogen-containing oral contraceptive in women with polycystic ovarian syndrome. Obstet Gynecol . 1982; 60 15-19 - 66 Palatsi R, Hirvensalo E, Liukko P. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Derm Venereol . 1984; 64 517-523 - 67 Weber-Diehl F, Unger R, Lachnit-Fixson U. Triphasic combination of ethinyl estradiol and gestodene. Contraception . 1992; 46 19-27 - 68 Azziz R, Gay F. The treatment of hyperandrogenism with oral contraceptives. Sem Reprod Endocrinol . 1989; 7 246-254 - 69 Lemay A, Dewailly S D, Grenier R. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethinyl estradiol and d,1-norgestrel. J Clin Endocrinol Metab . 1990; 71 8-14 - 70 Loudon N B, Kirkman R JE, Dewsbury J A. Double-blind comparison of Femodene and Microgynon. Eur J Obstet Gynecol Reprod Biol . 1990; 34 257-266 - 71 Wishart J M. An open study of Triphasil and Diane 50 in the treatment of acne. Australas J Dermatol . 1991; 32 51-54 - 72 Redmond G P, Olson W H, Lippman J S. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol . 1997; 89 615-622 - 73 Lucky A W, Henderson T A, Olson W H. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol . 1997; 37 746-754 - 74 Thorneycroft I H, Stanczyk F Z, Bradshaw K D. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception . 1999; 60 255-262 - 75 Burkman Jr T R. The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med . 1995; 98(suppl) 130S-136S - 76 Moore J, Kennedy S, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis (Cochrane Review). In: The Cochrane Library Issue 2. Oxford: Update Software; 1999 - 77 Cumming D C. Exercise-associated amenorrhea, low bone density, and estrogen replacement therapy. Arch Intern Med . 1996; 156 2193-2195 - 78 Chen E C, Brzyski R G. Exercise and reproductive dysfunction. Fertil Steril . 1999; 71 1-6 - 79 Warren M P, Stiehl A L. Exercise and female adolescents: effects on the reproductive and skeletal systems. J Am Med Womens Assoc . 1999; 54 115-138 - 80 Hergenroeder A C. Bone mineralization, hypothalamic amenorrhea, and sex steroid therapy in female adolescents and young adults. J Pediatr . 1995; 126 683-689 - 81 Spanos W J. Preoperative hormonal therapy of cystic adnexal masses. Am J Obstet Gynecol . 1973; 116 551-556 - 82 Steinkampf M P, Hammond K R, Blackwell R E. Hormonal treatment of functional ovarian cysts: a randomized, prospective study. Fertil Steril . 1990; 54 775-777 - 83 Daugherty J E. Treatment strategies for premenstrual syndrome. Am Fam Physician . 1998; 58 183-192 - 84 Barnhart K T, Freeman E, Sondheimer S. Premenstrual syndrome: a clinician's view. Med Clin North Am . 1995; 79 1457-1472 - 85 Sulak P J, Cressman B E, Waldrop E, Holleman S, Kuehl T J. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol . 1997; 89 179-183 - 86 Silberstein S D, Merriam G R. Sex hormones and headache. J Pain Symptom Manage . 1993; 8 98-114